North America contributed the largest share to the global respiratory inhaler devices market owing to high prevalence of chronic respiratory diseases with major impact of Asthma and COPD.
Increasing fatalities due to chronic respiratory disorders worldwide, the demand for respiratory inhaler devices is anticipated to ramp-up in coming years. The respiratory inhaler devices help in effective delivery of medication directly into the airway to lungs.
Some key players operating in the respiratory inhaler devices market include AstraZeneca plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc., Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding, and Teva Pharmaceutical Industries Ltd.
Based on disease type, the respiratory inhaler devices market is segmented into asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and others.
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved